The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy: A Breast International Group (BIG) 1-98 sub-analyses.
 
Jose Pablo Leone
Research Funding - Kazia Therapeutics (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Seagen (Inst)
 
Bernard F. Cole
No Relationships to Disclose
 
Meredith M. Regan
Consulting or Advisory Role - Ipsen (Inst); Merck
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Dendreon (Inst); Ferring (Inst); Ipsen (Inst); Ipsen (Inst); Janssen (Inst); Medivation (Inst); Merck (Inst); Millenium Pharamceuticals (Inst); Novartis (Inst); OncoGenex (Inst); Pfizer (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst); Sotio (Inst); TerSera (Inst); Veridex (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Beat J. K. Thurlimann
Stock and Other Ownership Interests - Novartis; Novartis (I); Roche; Roche (I)
Consulting or Advisory Role - Amgen; AstraZeneca; Lilly; Pfizer; Roche
Travel, Accommodations, Expenses - Roche
 
Alan S. Coates
No Relationships to Disclose
 
Aron Goldhirsch
No Relationships to Disclose
 
Angelo Di Leo
Honoraria - Amgen; AstraZeneca; Bayer; Celgene; Eisai; Genomic Health; Lilly; Novartis; Pfizer; Pierre Fabre; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Celgene; Daiichi Sankyo; Eisai; Genentech; Genomic Health; Ipsen; Lilly; Novartis; Pfizer; Pierre Fabre; Puma Biotechnology; Roche
Research Funding - AstraZeneca; Novartis; Pfizer
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Celgene; Daiichi Sankyo; Eisai; Lilly; Novartis; Pfizer; Pierre Fabre; Puma Biotechnology; Roche
 
Marco Colleoni
Honoraria - Novartis
Consulting or Advisory Role - AstraZeneca; Celldex; OBI Pharma; Pfizer; Pierre Fabre; Puma Biotechnology
 
Ines Maria Vaz Duarte Luis
Honoraria - AstraZeneca; Kephren; Novartis
Consulting or Advisory Role - Ipsen
 
Nancy U. Lin
Consulting or Advisory Role - Daiichi Sankyo; Genentech/Roche; Novartis; Puma Biotechnology; Seagen
Research Funding - Genentech; Novartis; Pfizer; Seagen
Patents, Royalties, Other Intellectual Property - Royalties for chapter in Up-to-Date regarding management of breast cancer brain metastases